NEW YORK, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Acelyrin, Inc. (NASDAQ:SLRN), and The Clorox Company (NYSE:CLX). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
Acelyrin, Inc. (NASDAQ:SLRN)
On or around May 5, 2023, Acelyrin conducted its initial public offering ("IPO"), selling 30 million shares of common stock priced at $18.00 per share. Then, on September 11, 2023, after the markets closed, Acelyrin announced disappointing top-line results from Part B of the Phase 2b/3 trial evaluating izokibep, the Company's lead drug candidate, for the treatment of moderate-to-severe hidradenitis suppurativa. Specifically, izokibep failed to show statistically significant reduction in ...